Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy

Completed · Phase 2 · Has a placebo group

Conditions studied: Hypercholesterolemia

In brief

Evaluation of the clinical profile (lipid efficacy, safety and PK) across a number of doses of CIVI 007, a PCSK9 inhibitor. Patients to be evaluated will be on a stable background of statin therapy with or without ezetimibe.

Key facts

Study ID

NCT04164888

Run by

Civi Biopharma, Inc.

People needed

49

Starts

2019-11-11

Expected to finish

2020-11-17

Last updated by the study team

2025-02-13

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Jacksonville, Florida, United States
• Research Site — Port Orange, Florida, United States
• Research Site — Indianapolis, Indiana, United States
• Research Site — Louisville, Kentucky, United States
• Research Site — Cincinnati, Ohio, United States
• Research Site — Munroe Falls, Ohio, United States
• Research Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.